Diagnostics compliance issues reduce Abbott's margins
This article was originally published in Clinica
The ongoing struggle at Abbott Diagnostics to bring US production facilities up to GMP standard led to a reduction in Abbott Laboratories' gross margin ratio in the first quarter of 2003. The compliance issues were also behind a 10% drop in US diagnostics sales to $270m, although this had been expected. Another reason for the declining sales was the discontinuation of two low-margin infection tests at the end of last year (see Clinica No 1042, p 11).